Landon Capital


Elevation Oncology, Inc. (NASDAQ:ELEV) has unveiled the extension of its Phase 1 clinical trial for EO-3021, a promising cancer therapy, marking the dosing of the inaugural patient in Japan. This expansion represents a strategic move in the company’s mission to pioneer treatments for solid tumors grappling with considerable unmet medical needs.

EO-3021 stands as a beacon of hope in the realm of cancer treatment, being a clinical-stage antibody drug conjugate (ADC) meticulously designed to target Claudin 18.2, a protein prevalent in gastric, gastroesophageal junction, pancreatic, and esophageal cancers. The primary objective of the trial remains centered on evaluating the therapy’s safety, tolerability, and preliminary anti-tumor efficacy.

Dr. Valerie Malyvanh Jansen, the esteemed Chief Medical Officer at Elevation Oncology, exudes confidence in the venture’s expansion into Japan, recognizing the country’s high incidence of gastric cancer cases. Dr. Kohei Shitara, serving as the trial’s principal investigator, echoes this sentiment, envisioning EO-3021 as a potential game-changer in enhancing patient outcomes, despite recent strides in gastric cancer treatment modalities.

Dubbed as an open-label, multi-center endeavor (NCT05980416), the trial encompasses both dose escalation and expansion phases conducted across various sites spanning the United States and Japan. Additionally, the trial aims to elucidate the correlation between Claudin 18.2 expression levels and patients’ objective response rates.

Anticipated updates from the ongoing trial are slated for mid-2024, with a comprehensive dataset expected to emerge in the first half of 2025. Elevation Oncology retains exclusive rights for the development and commercialization of EO-3021 outside the purview of Greater China, further underlining its commitment to pioneering transformative cancer therapies.